AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14966636 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisomol sealer+gutta‐percha
Number of subjects: 288
Study 14966636 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitapex+gutta‐percha
Number of subjects: 288
Study 14966636 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisomol sealer+gutta‐percha after drainage
Number of subjects: 288
Study 14966636 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitapex+gutta‐percha after drainage
Number of subjects: 288
Study 10631217 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral vein catheterization
Number of subjects: 124
Study 8820362 — intervention group
Group type: EXPERIMENTAL
Intervention: Provox VP
Number of subjects: 158
Study 8820362 — intervention group
Group type: EXPERIMENTAL
Intervention: Groningen VP
Number of subjects: 158
Study 8820362 — intervention group
Group type: EXPERIMENTAL
Intervention: Nijdam VP
Number of subjects: 158
Study 8820362 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 158
Study 1384148 — intervention group
Group type: EXPERIMENTAL
Intervention: BIP regimen (ifosfamide, cisplatin, bleomycin)
Number of subjects: 66
Study 1384148 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 66
Study 3876325 — intervention group
Group type: EXPERIMENTAL
Intervention: sulphamoxole 3200 mg/trimethoprim 640 mg (single dose)
Number of subjects: 135
Study 3876325 — intervention group
Group type: EXPERIMENTAL
Intervention: trimethoprim 700 mg (single dose)
Number of subjects: 135
Study 3876325 — intervention group
Group type: COMPARATOR
Intervention: sulphamoxole 800 mg/trimethoprim 160 mg (twice daily for five days)
Number of subjects: 135
Study 30052825 — intervention group
Group type: EXPERIMENTAL
Intervention: S66913 (5 mg, 25 mg, or 100 mg orally per day)
Number of subjects: 58
Study 30052825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 30225880 — intervention group
Group type: EXPERIMENTAL
Intervention: Data provided through the patient portal
Number of subjects: 128
Study 30225880 — intervention group
Group type: COMPARATOR
Intervention: Data provided through postal mail
Number of subjects: 128
Study 26451761 — intervention group
Group type: EXPERIMENTAL
Intervention: EGF
Number of subjects: 86
Study 26451761 — intervention group
Group type: EXPERIMENTAL
Intervention: bFGF
Number of subjects: 86
Study 26451761 — intervention group
Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 86
Study 26451761 — intervention group
Group type: EXPERIMENTAL
Intervention: EGF and bFGF
Number of subjects: 86
Study 26451761 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 86
Study 24594248 — intervention group
Group type: EXPERIMENTAL
Intervention: I-gel
Number of subjects: 45
Study 24594248 — intervention group
Group type: EXPERIMENTAL
Intervention: ILMA Fastrach
Number of subjects: 45
Study 23126312 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient directed self management of pain (PaDSMaP)
Number of subjects: 665
Study 23126312 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 665
Study 23126312 — intervention group
Group type: EXPERIMENTAL
Intervention: PaDSMaP
Number of subjects: 665
Study 20044066 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 315
Study 20044066 — intervention group
Group type: EXPERIMENTAL
Intervention: Active smokers
Number of subjects: 315
Study 20044066 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report vs urine cotinine level
Number of subjects: 315
Study 18049889 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (ganirelix 0.25 mg/d for 3 days)
Number of subjects: 35
Study 18049889 — intervention group
Group type: COMPARATOR
Intervention: Control (self-controlled cycle without GnRH antagonist)
Number of subjects: 35
Study 16260353 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide 120 mg
Number of subjects: 12
Study 16260353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12135593 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (beta-carotene, vitamins C and E, zinc, and selenium)
Number of subjects: 36
Study 12135593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 11461739 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intensive training (6 times per week for 3 months)
Number of subjects: 62
Study 11461739 — intervention group
Group type: COMPARATOR
Intervention: Routine training (2 times per week for 3 months)
Number of subjects: 62
Study 9828907 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with GnRH analogue leuprolide acetate (0.3 mg/kg im every 28 days) and rhGH (0.1 U/kg/day, sc, 6 days a week) for 30.0 ± 5.2 months
Number of subjects: 10
Study 9828907 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 10
Study 8172436 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose radiation (2000 cGy to lymph node areas and 1000 to 1500 cGy to other involved organ sites)
Number of subjects: 278
Study 8172436 — intervention group
Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 278
Study 8172436 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose radiation and No further treatment
Number of subjects: 278
Study 2894764 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate 50 mg twice a day
Number of subjects: 20
Study 2894764 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate
Number of subjects: 20
Study 2894764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29567762 — intervention group
Group type: EXPERIMENTAL
Intervention: HHS (Hip-Hop Stroke) intervention
Number of subjects: 3070
Study 29567762 — intervention group
Group type: COMPARATOR
Intervention: Attentional control (nutrition classes)
Number of subjects: 3070
Study 29327548 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM synthetic rehabilitation (manipulative therapy, joint mobilization, soaking-washing with Chinese medicinal herbs, functional exercise)
Number of subjects: 72
Study 29327548 — intervention group
Group type: COMPARATOR
Intervention: Functional exercise and soaking-washing with Chinese medicinal herbs (control group)
Number of subjects: 72
Study 29327548 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip strength recovery (ipsilateral wrist)
Number of subjects: 72
Study 29327548 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety levels
Number of subjects: 72
Study 25531733 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 10 mg/kg as a bolus, 15 minutes before incision
Number of subjects: 0
Study 25531733 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 0
Study 24246119 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapy change
Number of subjects: 19
Study 24246119 — intervention group
Group type: COMPARATOR
Intervention: Standard care (reference group)
Number of subjects: 19
Study 21177312 — intervention group
Group type: EXPERIMENTAL
Intervention: Single IUI timed at 36 ± 2 h post-hCG (post-ovulation)
Number of subjects: 1146
Study 21177312 — intervention group
Group type: COMPARATOR
Intervention: Single IUI timed at 36 ± 2 h post-hCG (pre-ovulation)
Number of subjects: 1146
Study 21177312 — intervention group
Group type: EXPERIMENTAL
Intervention: Double IUI in pre-ovulatory cases
Number of subjects: 1146
Study 21177312 — intervention group
Group type: COMPARATOR
Intervention: Single IUI in pre-ovulatory cases
Number of subjects: 1146
Study 19029469 — intervention group
Group type: EXPERIMENTAL
Intervention: Torcetrapib plus atorvastatin
Number of subjects: 1656
Study 19029469 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin alone
Number of subjects: 1656
Study 17158419 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fructose diet (1.5 g fructose . kg body wt(‐1) . d(‐1) for 4 weeks)
Number of subjects: 7
Study 14581866 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 1004
Study 14581866 — intervention group
Group type: COMPARATOR
Intervention: HRT
Number of subjects: 1004
Study 10758964 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing (BiV)
Number of subjects: 13
Study 8828721 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscous carbomer eye drops
Number of subjects: 61
Study 8828721 — intervention group
Group type: COMPARATOR
Intervention: 1.4% polyvinyl alcohol‐based (PVA) eye drops
Number of subjects: 61
Study 1582625 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (E) 20‐40 mg daily
Number of subjects: 25
Study 1582625 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Channel Blockers (CCB): slow‐release nifedipine (40 mg) or long‐acting verapamil (120‐360 mg) daily
Number of subjects: 25
Study 29458318 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative oxygen therapy
Number of subjects: 1000
Study 29458318 — intervention group
Group type: COMPARATOR
Intervention: Standard care oxygen therapy
Number of subjects: 1000
Study 27251051 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab HYP 150 mg subcutaneous every 4 weeks
Number of subjects: 0
Study 27251051 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta-1a 30 mcg intramuscular once weekly
Number of subjects: 0
Study 27251051 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab HYP
Number of subjects: 0
Study 27251051 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta-1a
Number of subjects: 0
Study 26579947 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor skill training in children with DCD
Number of subjects: 41
Study 26579947 — intervention group
Group type: COMPARATOR
Intervention: Nontraining group of children with DCD
Number of subjects: 41
Study 26579947 — intervention group
Group type: COMPARATOR
Intervention: Typically developed children (control group)
Number of subjects: 41
Study 23614998 — intervention group
Group type: EXPERIMENTAL
Intervention: Preexposure prophylaxis (PrEP) with daily tenofovir disoproxil fumarate/emtricitabine
Number of subjects: 376
Study 23614998 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of PrEP through clinical trial or health insurance
Number of subjects: 376
Study 23614998 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of PrEP use
Number of subjects: 376
Study 23614998 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of PrEP on recruitment
Number of subjects: 376
Study 20092401 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin treatment with folic acid and vitamin B12 for 2 months (Group 2, n = 30)
Number of subjects: 59
Study 20092401 — intervention group
Group type: COMPARATOR
Intervention: No vitamin treatment (Group 1, n = 29)
Number of subjects: 59
Study 20092401 — intervention group
Group type: COMPARATOR
Intervention: Patients with stroke compared to controls (n = 64)
Number of subjects: 59
Study 19909082 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated split-virus influenza vaccine (TIV)
Number of subjects: 7652
Study 19909082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7652
Study 16469035 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (30, 60, 120, 240, 360, or 480 microg)
Number of subjects: 72
Study 16469035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 15055208 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer
Number of subjects: 0
Study 15055208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15055208 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta
Number of subjects: 0
Study 11571068 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive counselling
Number of subjects: 61
Study 11571068 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management
Number of subjects: 61
Study 11571068 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol‐focused couples therapy
Number of subjects: 61
Study 9240113 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention (cognitive-behavioral strategies)
Number of subjects: 0
Study 9240113 — intervention group
Group type: COMPARATOR
Intervention: Control group (brief advice)
Number of subjects: 0
Study 8501751 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort (DFZ)
Number of subjects: 34
Study 8501751 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (PRED)
Number of subjects: 34
Study 2881566 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (ED95 0.23 mg kg‐1)
Number of subjects: 30
Study 2881566 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (ED95 0.055 mg kg‐1)
Number of subjects: 30
Study 2881566 — intervention group
Group type: COMPARATOR
Intervention: Control group (no neuromuscular blocking drug)
Number of subjects: 30
Study 29754015 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led home visit intervention (4 home visits and 4 telephone calls)
Number of subjects: 0
Study 29754015 — intervention group
Group type: COMPARATOR
Intervention: Standard HF management (control)
Number of subjects: 0
Study 29754015 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led home visit intervention
Number of subjects: 0
Study 27489011 — intervention group
Group type: EXPERIMENTAL
Intervention: DPZS (7 mg Zn/d)
Number of subjects: 7641
Study 27489011 — intervention group
Group type: EXPERIMENTAL
Intervention: All supplemented groups
Number of subjects: 7641
Study 27489011 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive and TZS groups
Number of subjects: 7641
Study 27489011 — intervention group
Group type: COMPARATOR
Intervention: MSC (morbidity surveillance control)
Number of subjects: 7641
Study 24787564 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVILAS laser (30 ms pulse duration)
Number of subjects: 73
Study 24787564 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVILAS laser (100 ms pulse duration)
Number of subjects: 73
Study 24787564 — intervention group
Group type: EXPERIMENTAL
Intervention: PASCAL laser (30 ms pulse duration)
Number of subjects: 73
Study 24787564 — intervention group
Group type: EXPERIMENTAL
Intervention: PASCAL laser (100 ms pulse duration)
Number of subjects: 73
Study 24787564 — intervention group
Group type: COMPARATOR
Intervention: NAVILAS laser
Number of subjects: 73
Study 24787564 — intervention group
Group type: COMPARATOR
Intervention: PASCAL laser
Number of subjects: 73
Study 22867776 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine fibroid embolization
Number of subjects: 274
Study 22867776 — intervention group
Group type: EXPERIMENTAL
Intervention: Myomectomy
Number of subjects: 274
Study 22867776 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 274
Study 19457494 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine (40 mL)
Number of subjects: 60
Study 19457494 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine (40 mL)
Number of subjects: 60
Study 19457494 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline, 40 mL)
Number of subjects: 60
Study 19176705 — intervention group
Group type: EXPERIMENTAL
Intervention: Support and instruction for intrinsically motivated women
Number of subjects: 44
Study 19176705 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing for extrinsically motivated women
Number of subjects: 44
Study 19176705 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal breastfeeding counseling for successfully experienced women
Number of subjects: 44
Study 15836975 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild pressure application
Number of subjects: 14
Study 15836975 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate pressure application
Number of subjects: 14
Study 15836975 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional MRI during pressure application
Number of subjects: 14
Study 15836975 — intervention group
Group type: COMPARATOR
Intervention: Intensity and unpleasantness ratings
Number of subjects: 14
Study 15836975 — intervention group
Group type: COMPARATOR
Intervention: Pressure levels (painful or non-painful)
Number of subjects: 14
Study 12940468 — intervention group
Group type: EXPERIMENTAL
Intervention: Street Smart HIV intervention program
Number of subjects: 187
Study 12940468 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 187
Study 10482044 — intervention group
Group type: EXPERIMENTAL
Intervention: Eukalaemic potassium clamp (potassium supply)
Number of subjects: 20
Study 10482044 — intervention group
Group type: COMPARATOR
Intervention: Without potassium supply (decline in potassium monitored)
Number of subjects: 20
Study 8756273 — intervention group
Group type: EXPERIMENTAL
Intervention: Do-it-yourself method (participants think about how to build the wall and then draw it)
Number of subjects: 0
Study 8756273 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance-to-goal evaluation method (participants evaluate how their drawn wall prevents passage)
Number of subjects: 0
Study 1880318 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose methotrexate (MTX)
Number of subjects: 15
Study 1880318 — intervention group
Group type: COMPARATOR
Intervention: Placebo (folic acid)
Number of subjects: 15
Study 6179339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of long-term continuous steroid application
Number of subjects: 58
Study 29617743 — intervention group
Group type: EXPERIMENTAL
Intervention: Head orthosis therapy
Number of subjects: 45
Study 29617743 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 45
Study 29617743 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 29617743 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients with DP
Number of subjects: 45
Study 27062690 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led telephone follow-up (TFU)
Number of subjects: 259
Study 27062690 — intervention group
Group type: COMPARATOR
Intervention: Hospital follow-up (HFU)
Number of subjects: 259
Study 24714185 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 699
Study 24714185 — intervention group
Group type: COMPARATOR
Intervention: Surgical resection (SR)
Number of subjects: 699
Study 24199987 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 1300
Study 24199987 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid intake
Number of subjects: 1300
Study 24199987 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium excretion
Number of subjects: 1300
Study 24199987 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1300
Study 24199987 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine clearance
Number of subjects: 1300
Study 24199987 — intervention group
Group type: EXPERIMENTAL
Intervention: Living in the German-speaking part of Switzerland
Number of subjects: 1300
Study 24199987 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 1300
Study 24199987 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 1300
Study 24199987 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 1300
Study 24199987 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of meat and cold cut
Number of subjects: 1300
Study 21317148 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (300 mg)
Number of subjects: 820
Study 21317148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 820
Study 18789189 — intervention group
Group type: EXPERIMENTAL
Intervention: Body oriented psychological therapy (BPT)
Number of subjects: 0
Study 18182731 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective ventilation strategy
Number of subjects: 34
Study 18182731 — intervention group
Group type: COMPARATOR
Intervention: Traditional ventilation strategy plus PEEP
Number of subjects: 34
Study 15062138 — intervention group
Group type: EXPERIMENTAL
Intervention: Interstitial pulsed-dose-rate (PDR) brachytherapy (DREF=20-60 Gy)
Number of subjects: 43
Study 15062138 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients treated with interstitial pulsed-dose-rate (PDR) brachytherapy
Number of subjects: 43
Study 15062138 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated with curative intention
Number of subjects: 43
Study 15062138 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy or hyperthermia
Number of subjects: 43
Study 15062138 — intervention group
Group type: EXPERIMENTAL
Intervention: Interstitial pulsed-dose-rate (PDR) brachytherapy
Number of subjects: 43
Study 11032084 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference products as per WHO List of International Comparator Pharmaceutical Products (CPP)
Number of subjects: 0
Study 11032084 — intervention group
Group type: COMPARATOR
Intervention: Brand products sold locally
Number of subjects: 0
Study 11032084 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic drugs developed using the CPP
Number of subjects: 0
Study 11032084 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase III clinical studies on products manufactured in a single site
Number of subjects: 0
Study 11032084 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulations with maintained safety and efficacy
Number of subjects: 0
Study 9127120 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-volume-pulse biofeedback followed by cognitive behavioral therapy (Group I)
Number of subjects: 38
Study 9127120 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral therapy followed by blood-volume-pulse biofeedback (Group II)
Number of subjects: 38
Study 1337291 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.015 mg/kg)
Number of subjects: 10
Study 1337291 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.15 mg/kg)
Number of subjects: 10
Study 1337291 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 10
Study 1337291 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (both doses)
Number of subjects: 10
Study 1337291 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (low dose)
Number of subjects: 10
Study 1337291 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-endorphin levels
Number of subjects: 10
Study 3025927 — intervention group
Group type: COMPARATOR
Intervention: Org 2766
Number of subjects: 156
Study 30057048 — intervention group
Group type: EXPERIMENTAL
Intervention: Momordica charantia (500 mg per capsule, three times daily for 3 months)
Number of subjects: 75